#NewAseBioMember | “AseBio is the meeting point for all companies that aim to contribute to science through the biotechnology sector”

AseBio.What does your company's work bring to the table and what is its strength?

Patricia Ortega Muñoz. Meisys is a scientific consultancy that offers pharma companies and other entities in the healthcare sector the outsourcing of services typically handled by their medical departments. From Medical Information, Pharmacovigilance, and Regulatory services to Medical Affairs, Quality Affairs, and Medical Governance, we aim to provide a comprehensive solution as their main provider of medical-scientific knowledge.

Our strength: expertise and rigor. We have been helping healthcare companies for over 15 years and have a deep understanding of the biosanitary field. We see quality processes as essential to achieving a high level of excellence. It’s not just a way of speaking: we truly uphold rigor as a distinguishing value. Also our clients highly value the closeness and approachability of our team.
 

AseBio.  What is AseBio for you?

Patricia Ortega Muñoz. For Meisys, AseBio is the meeting point for all companies that aim to contribute to science through the biotechnology sector. We don’t want to miss out on being part of it, as we firmly believe in the power of collaboration and the need to share knowledge, innovation, and a commitment to the development of the sector and its impact on society.

AseBio. When did you first hear about AseBio?

Patricia Ortega Muñoz. At the 2021 Spanish Association of Pharmaceutical Industry Medicine (AMIFE) congress, one of our clients told me about AseBio. Since then, we’ve been closely following your work. Over this time, we’ve seen that we can contribute significantly to your association in a direct way and that being part of this community could greatly enrich us.

AseBio. What do you expect from being part of an association like AseBio?

Patricia Ortega Muñoz. We hope AseBio will enable us to connect more closely with biotech companies to collaborate in the exchange of knowledge, project efficiency, and helping to solve challenges affecting the sector.

AseBio. What is the biggest challenge facing the biotech sector or your company?

Patricia Ortega Muñoz. Without a doubt, I believe our biggest challenge is to continue maintaining excellence in our services amid the constant innovations and advancements in biotechnology.